'U.S. approval for psychedelic drug MDMA nears after success in clinic' -Labiotech
Portfolio Pulse from Benzinga Newsdesk
The U.S. is nearing approval for the psychedelic drug MDMA following successful clinical trials. This development could potentially impact the stock of Enveric Biosciences (ENVB), a company involved in the development of novel therapeutic compounds.
September 22, 2023 | 5:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The potential U.S. approval of MDMA could positively impact Enveric Biosciences, which is involved in the development of novel therapeutic compounds.
The news of potential U.S. approval for MDMA, a psychedelic drug, could have a positive impact on Enveric Biosciences (ENVB) as it is involved in the development of novel therapeutic compounds. This could potentially open up new avenues for the company's research and development, and possibly lead to increased investor interest.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80